Neurocrine Biosciences Income Statement (2010-2026) | NBIX

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	288.90M	296.00M	312.00M	310.60M	20.00M	387.90M	412.00M	420.40M	452.70M	498.80M	515.20M	515.30M	590.20M	622.10M	627.70M	572.60M	687.50M	794.90M	805.50M	814.50M
Cost of Revenue (Quarter)	3.10M	4.20M	4.10M	4.60M	4.80M	6.10M	7.70M	8.50M	11.50M	11.20M	8.50M	7.50M	9.20M	8.00M	9.30M	9.20M	11.30M	14.00M	17.60M	13.80M
Gross Profit (Quarter)	285.80M	291.80M	307.90M	306.00M	15.20M	381.80M	404.30M	411.90M	441.20M	487.60M	506.70M	507.80M	581.00M	614.10M	618.40M	563.40M	676.20M	780.90M	787.90M	800.70M
Operating items
Research & Development (Quarter)	74.80M	5.40M	87.40M	7.30M	30.00M	107.70M	118.00M	139.50M	145.80M	142.20M	137.50M	5.00M	7.50M	195.00M	185.60M	263.20M	15.00M	250.00M	258.20M	296.20M
Selling, General & Administrative (Quarter)	143.20M	154.60M	156.50M	200.70M	182.80M	186.30M	182.90M	242.70M	221.80M	204.20M	218.90M	243.10M	242.00M	234.30M	287.80M	276.50M	286.30M	291.60M	301.80M	318.50M
Other Operating Expenses (Quarter)	8.10M	91.50M	104.40M	99.50M	110.70M	6.10M	7.70M	152.40M	11.50M	11.20M	8.50M	167.90M	195.30M	9.00M	12.30M		240.60M	14.30M	34.60M	28.60M
Operating Expenses (Quarter)	226.10M	251.50M	348.30M	307.50M	323.50M	300.10M	308.60M	534.60M	379.10M	357.60M	364.90M	416.00M	444.80M	438.30M	485.70M	549.00M	541.90M	555.90M	594.60M	621.10M
Operating Income (Quarter)	62.80M	44.50M	-36.30M	3.10M	54.70M	87.80M	103.40M	-114.20M	73.60M	141.20M	150.30M	99.30M	145.40M	183.80M	142.00M	23.60M	145.60M	239.00M	210.90M	193.40M
EBIT (Quarter)	62.80M	44.50M	-36.30M	3.10M	54.70M	87.80M	103.40M	-114.20M	73.60M	141.20M	150.30M	99.30M	145.40M	183.80M	142.00M	23.60M	145.60M	239.00M	210.90M	193.40M
Non-operating items
Interest & Investment Income (Quarter)	0.90M	0.80M	0.70M	1.00M	1.60M	0.20M	1.30M	9.80M	10.70M	14.50M	18.90M	22.30M	22.80M	23.40M	22.50M	21.70M	20.60M	22.20M	25.80M	28.10M
Other Non Operating Income (Quarter)					-70.00M
Non Operating Income (Quarter)	-5.30M	-14.00M	22.50M	18.30M	-78.00M	10.10M	14.50M	10.90M	48.00M	-25.60M	47.90M	-64.80M	-46.80M	6.50M	20.60M	-8.90M	13.90M	52.80M	28.50M	53.40M
Net income details
EBT (Quarter)	57.50M	30.50M	-13.80M	21.40M	-23.30M	97.90M	117.90M	-103.30M	121.60M	115.60M	198.20M	34.50M	98.60M	190.30M	162.60M	14.70M	159.50M	291.80M	239.40M	246.80M
Tax Provisions (Quarter)	15.20M	8.00M	-6.50M	7.50M	-6.40M	29.40M	28.90M	-26.70M	26.10M	32.50M	50.50M	-8.90M	33.60M	60.50M	59.50M	6.80M	52.00M	82.30M	85.70M	48.90M
Profit After Tax (Quarter)	42.30M	22.50M	-7.30M	13.90M	-16.90M	68.50M	89.00M	-76.60M	95.50M	83.10M	147.70M	43.40M	65.00M	129.80M	103.10M	7.90M	107.50M	209.50M	153.70M	197.90M
Equity Income (Quarter)		-8.20M	28.40M	19.90M	-7.40M	11.10M	7.20M	2.20M	37.30M	-40.10M	29.00M	1.60M	-19.90M	-16.90M	-1.90M	-30.60M	-6.70M	30.60M	2.70M	25.30M
Income from Continuing Operations (Quarter)	42.30M	22.50M	-7.30M	13.90M	-16.90M	68.50M	89.00M	-76.60M	95.50M	83.10M	147.70M	43.40M	65.00M	129.80M	103.10M	7.90M	107.50M	209.50M	153.70M	197.90M
Consolidated Net Income (Quarter)	42.30M	22.50M	-7.30M	13.90M	-16.90M	68.50M	89.00M	-76.60M	95.50M	83.10M	147.70M	43.40M	65.00M	129.80M	103.10M	7.90M	107.50M	209.50M	153.70M	197.90M
Income towards Parent Company (Quarter)	42.30M	22.50M	-7.30M	13.90M	-16.90M	68.50M	89.00M	-76.60M	95.50M	83.10M	147.70M	43.40M	65.00M	129.80M	103.10M	7.90M	107.50M	209.50M	153.70M	197.90M
Net Income towards Common Stockholders (Quarter)	42.30M	22.50M	-7.30M	13.90M	-16.90M	68.50M	89.00M	-76.60M	95.50M	83.10M	147.70M	43.40M	65.00M	129.80M	103.10M	7.90M	107.50M	209.50M	153.70M	197.90M
Additional items
EPS (Basic) (Quarter)	0.45	0.24	-0.08	0.15	-0.18	0.72	0.92	-0.79	0.98	0.85	1.51	0.43	0.64	1.28	1.03	0.08	1.09	2.11	1.54	1.97
EPS (Weighted Average and Diluted) (Quarter)	0.43	0.23	-0.07	0.14	-0.18	0.69	0.89	-0.79	0.95	0.82	1.46	0.42	0.63	1.24	1.00	0.08	1.06	2.04	1.48	1.91
Shares Outstanding (Weighted Average) (Quarter)	94.40M	94.70M	94.60M	95.30M	95.60M	95.80M	95.80M	97.10M	97.40M	97.50M	97.70M	99.80M	100.80M	101.10M	100.40M	99.70M	99.00M	99.40M	99.50M	100.50M
Shares Outstanding (Diluted Average) (Quarter)	97.70M	97.90M	97.90M	97.60M	95.60M	99.00M	98.90M	97.10M	100.30M	100.60M	101.00M	103.60M	103.90M	104.30M	103.70M	102.50M	101.00M	102.00M	102.50M	103.40M
EBITDA (Quarter)	42.00M	22.20M	-9.40M	6.30M	-19.80M	66.70M	95.10M	-71.40M	97.10M	82.50M	156.40M	39.70M	64.20M	141.80M	94.40M	11.10M	111.00M	210.20M	153.60M	185.20M
Interest Expenses (Quarter)	6.20M	6.60M	6.60M	2.60M	2.20M	1.20M	1.10M	1.10M	1.30M	1.10M	1.10M	1.10M
Tax Rate (Quarter)	26.43%	26.23%	47.10%	35.05%	27.47%	30.03%	24.51%	25.85%	21.46%	28.11%	25.48%	-25.80%	34.08%	31.79%	36.59%	46.26%	32.60%	28.20%	35.80%	19.81%

Research Tools

Neurocrine Biosciences Income Statement (2010-2026) | NBIX

Create an account

Sign In

Reset Password